||A major contributor to this article appears to have a close connection with its subject. (September 2010)|
|Type||Publicly traded Aktieselskab (OMX: NZYM B)|
|Key people||Henrik Gürtler (Chairman), Peder Holk Nielson (President and CEO)|
|Revenue||DKK 10.510 billion (2011)1|
|Operating income||DKK 2.340 billion (2011)1|
|Profit||DKK 1.828 billion (2011)1|
In 1925 the brothers Harald and Thorvald Pedersen founded Novo Terapeutisk Laboratorium with the aim to produce insulin. In the mid 1930’s Novozymes build the first office in Copenhagen. In 1941 Novozymes launches its first enzyme, trypsin, extracted from the pancreas of animals and used to soften leather.
The company was the first to produce enzymes by fermentation using bacteria in 1952. In the late 1980’s Novozymes presented the world’s first fat-splitting enzyme for detergents manufactured with genetically engineered microorganisms. In the 2000’s Novozymes expanded through acquisition of several companies focusing on business outside the core enzyme business. Amongst them were the Brazilian bioagricultural company Turfal and German pharmaceutical, chemical and life science company EMD/Merck Crop BioScience Inc. These acquisitions made Novozymes the largest player in sustainable solutions for the agricultural biological industry.
Novozymes' business is divided into three areas: Enzymes for industrial use, microorganisms, and biopharmaceutical ingredients accounting for respectively 90%, 7% and 3% of sale, respectively (2011).3 Novozymes markets approximately 700 different products worldwide.
Enzymes are divided into the following categories:
- Household Care Enzymes. Enzymes used in laundry detergents and automatic dish washing machines.
- Food & Beverage Enzymes. Food & Beverage enzymes include products for the baking, brewing, beverage alcohol, fruit juice and wine industries, and other food industries such as the dairy industry and the oils & fats industry.4
- Bioenergy Enzymes. Enzymes used for conversion of starch and organic waste into fermentable sugars for the bioenergy industry
- Feed and other technical enzymes. The most important products in this business area are enzymes for the starch, textile and the animal feed industries, as well as enzymes for the leather and forest products industries and various other smaller industries.
Biopharmaceutical ingredients consist of regulatory-compliant, protein based products and technologies dedicated to the biopharmaceutical industry, adding value through efficiency - from manufacture to final drug formulation and drug delivery.
The microorganisms business area includes microorganisms for:
- Institutional and household cleaning
- Wastewater treatment
The Novozymes A share capital is held by Novo A/S, a wholly owned subsidiary of the Novo Nordisk Foundation. In addition, Novo A/S holds 5,826,280 B shares, which overall gives Novo A/S 25.5% of the total share capital and 70.1% of the votes.
Novozymes A/S' B shares are listed on the NASDAQ OMX Nordic and are traded under the abbreviated name NZYM B and the ID code/ISIN DK0010272129. The B shares are issued in units of DKK 10.
Each A share carries the right to cast one hundred votes at the company's shareholders' meeting, each B share the right to cast ten votes.
- "Annual Report 2011". Novozymes. Retrieved 21 January 2011.
- "Annual Report 2012". Novozymes. Retrieved 2 February 2012.
- The Novozymes Report 2010
- Official website
- Fahey, Jonathan (April 22, 2010). "Are We Getting Closer to 'Clean' Ethanol?". Forbes. Archived from the original on January 23, 2013. Retrieved May 29, 2010.
- Forbes Magazine: "100 Corporations That Will Survive 100 Years" (January 28, 2009)